CLAIMS

1. Use of a compound in the manufacture of a medicament for the treatment of a cell proliferative disease by the stimulation of IL-12p70 production and IFN-γ production, which compound is selected from:

tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alaninate, or a pharmaceutically acceptable salt, hydrate or solvate thereof; and

N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alanine.

2. The use of a compound according to claim 1, wherein the compound is tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alaninate, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

3. The use of a compound according to claim 1 or claim 2, wherein the compound is the ethanesulphonate salt of tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alaninate.

4. Use of a composition in the manufacture of a medicament for the treatment of a cell proliferative disease by the stimulation of IL-12p70 production and IFN-γ production, wherein the composition comprises a compound as defined in any one of claims 1 to 3 together with one or more pharmaceutically acceptable carriers and/or excipients.

5. The use of a compound as defined in any one of claims 1 to 3, or the use of a composition as defined in claim 4, wherein the compound or composition is for use in the treatment of cancer by stimulation of IL-12p70 production and IFN-γ production.

6. The use according to claim 5, wherein the compound or composition is for use in the treatment of head and neck cancer, prostate cancer, bladder cancer, acute myeloid cancer, cervical cancer, gastric cancer, hepatocellular carcinoma, mesothelioma, multiple myeloma or esophageal cancer.